ÂÜÀòÂÒÂ×

Jakob Lindberg was appointed as CSO in 2020.

In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB.

Jakob was CEO of Oncopetides AB between 2011 and 2020. His previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.

Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.